George Golumbeski
George Golumbeski's purchase track record
George Golumbeski has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/21/2022 | STTK | $200K | +29.0% | -22.5% | -16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
UBS initiates coverage on Shattuck Labs with $17 price target. UBS has started covering Shattuck Labs, assigning a price target of $17. This new analyst view comes as the company prepares to present research at UEG Week 2026. The stock is currently trading near its 52-week low, making this fresh institutional attention a notable development for the company.
Transaction History
| ABOS | ▲ Buy | Grant | 35,500 | $0 | 6/3/2026 | View on chart |
| STTK | ▲ Buy | Open Market | 28,330 | $103K | 4/26/2022 | View on chart |
| STTK | ▲ Buy | Open Market | 234 | $859 | 4/22/2022 | View on chart |
| STTK | ▲ Buy | Open Market | 26,049 | $96K | 4/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List
Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List. Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.